EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Says it expects to record revenue growth beginning in its fourth quarter ending March 31, noting the ‘pipeline of additional products in development continues to expand, underpinning future continued growth’. Adds that EDX management is exploring ‘point of care and laboratory testing solutions’ at both its own labs and with others in the life sciences sector. Says in addition to recently announced distribution agreements with Caris Life Sciences Inc and Curesponse, will later this month will bring to market a ‘comprehensive hereditary genetic risk testing products and services, for cancer and heart disease’.

‘There is growing and compelling evidence of the demand from healthcare professionals and patients for faster and better genomic and genetic diagnostic tests and services and digital diagnostics hold the potential to unlock the large-scale benefits of personalised medicine,’ EDX says, adding it has ‘the opportunity over the next five years to provide healthcare professionals with a range of best-in-class digital diagnostic products and services backed up with excellent operational resources’.

Current share price: 11.50 pence

12-month change: quadrupled from 2.88 pence

Copyright 2024 Alliance News Ltd. All Rights Reserved.